Opicapone (Ongentys) - A COMT Inhibitor for Parkinson ' s Disease
Date: January 11, 2021
Issue #:
1615Summary:
The FDA has approved opicapone (Ongentys–
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience " off " episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Apokyn Apomorphine Carbidopa/levodopa Comtan Dopamine Entacapone Epinephrine Inbrija istradefylline Kynmobi Movapo Nourianz Ongentys opicapone Parkinson ' s disease Phenelzine Rytary selegeline Stalevo Tasmar To Source Type: research